Bengaluru: Medgenome Labs, Research and Diagnostic Company Genomics-Driven Bengaluru, has launched services directly to customers, offering advanced technology such as the order of the next generation on the threshold of consumer doors.
The new genessense – a new category introduced by Medgenome – focuses on re-modeling genomic space with test-supported tests that provide insight into a person’s health before the onset of symptoms.
VL Ramprasad, CEO, Medgenome, told Toi: “We have thought about this for about a year now but the pandemic causes a delay.
We have launched two types of tests: one for CAD (coronary artery) and other for drug metabolism and profiling Risk.
People can start ordering tests at a cost.
“He said that in the next year, the company will add at least four more tests that can handle diabetes, hypertension and more.
Ramprasad said the cardiogen test was intended for CAD, designed for all individuals over 18 years.
It not only predicts the risk of inherited heart disease, but also provides an opportunity to manage disease.
“This predicts the incidence of early CAD with almost 90% accuracy,” said Ramprasad.
This test helps predict a person’s chances of developing heart conditions even before the body shows any symptoms and places a number at this risk – a cardiogen risk score (KRS).
“The KRS is determined through a variation assessment in more than six million genes,” said the company.
“The association of all this unique variation gives us a polygenic risk score that we call KRS.
Based on KRS, one is classified as ‘high risk, moderate or average’, an insight that will help someone take preventive action,” said the company.
Pharmacogenomics Other test tests – Caorgeben – is a precision pharmacogenomic test for individuals who examine metabolism more than 45 drugs and drug classes.
The curegen will notify someone if they respond differently to these drugs and if they need to realize that some of these drugs can cause a detrimental reaction based on their genomic profiles.
It is also a test that someone needs only in their lives.
While the Genissense insisted on following the latest guidelines prescribed by the Consortium of Pharmacogenetic Clinical Implementation (CPIC) and PharmAGKB which included more than 45 classes of medicines / drugs in 10 categories of disease, the company said Cuseben only saw strong drugs in accordance with appearance.
Guidelines.
“Obengen utilizes microarray / sequencing and sophisticated drugs utilizing the next generation sequencing (NGS) to arrive at the results.
NGS takes more than 250 important variants passed by older techniques.
Medgenome – Parent Genessense Company – is the first to introduce NGS techniques in India In 2013, “said the company.